rituximab
not Tagged
['lysa']
for those attending asco, any theories as to why the os benefit initially seen in the lysa lyma mcl trial, is no longer significant (p=0.09) with longer f/u? abstract says no increase in infectious deaths or relapses after r maint ended 
Lymphoma, Malignant Hematology, Drug Development, Transplant & Cellular Therapy, and other medical news & views. Physician ≠ Provider